Servier and Taiho Pharmaceutical Co., Ltd. Announced on 6/21/2-18 clinical data from the pivotal Phase III trial (TAGS) for Lonsurf (trifluridine and tipiracil, TAS-102) which showed significant improvement in overall survival (OS) for the treatment of patients with refractory metastatic gastric cancer (HR=0.69 [95% IC 0.56-0.85], p=0.0003).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,